STOCK TITAN
  1. Home
  2. News
  3. NRIX

Nurix Therapeutics Inc - NRIX STOCK NEWS

Welcome to our dedicated news page for Nurix Therapeutics (Ticker: NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nurix Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nurix Therapeutics's position in the market.

News
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Rhea-AI Summary
Nurix Therapeutics, Inc. (Nasdaq: NRIX) closed a public offering of 11,916,667 shares at $15.00 per share, with additional shares purchased by underwriters. The offering also included pre-funded warrants. The net proceeds totaled approximately $188.6 million. J.P. Morgan Securities , Piper Sandler & Co., and Stifel, Nicolaus & Company, Incorporated were the joint book-running managers. The offering was made under a shelf registration statement filed with the SEC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.89%
Tags
offering
-
News
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
Rhea-AI Summary
Nurix Therapeutics, Inc. (Nasdaq: NRIX) announces the pricing of an upsized underwritten public offering, including shares of common stock and pre-funded warrants, with expected gross proceeds of $175.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.73%
Tags
offering
-
News
Nurix Therapeutics Announces Proposed Public Offering
Rhea-AI Summary
Nurix Therapeutics, Inc. (Nasdaq: NRIX) announces a $125 million public offering of common stock and pre-funded warrants to fund clinical development and research activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.73%
Tags
offering
News
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
Rhea-AI Summary
Nurix Therapeutics, Inc. (NRIX) reported strong financial results for Q1 2024, highlighted by extended collaborations with Gilead Sciences and Sanofi. The company presented positive clinical data for NX-5948, demonstrating clinical responses in patients with CNS lymphoma and CLL. Nurix is part of a team awarded in the Cancer Grand Challenges competition, aiming to develop targeted protein degraders for childhood cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.24%
Tags
earnings
-
News
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
Rhea-AI Summary
Nurix Therapeutics, Inc. (NRIX) presented new case studies at the AACR 2024 Annual Meeting demonstrating clinical responses in patients with B cell malignancies, CLL, and PCNSL, with CNS involvement. The data showed promising results for NX-5948 in treating cancers with CNS involvement and potential applications in autoimmune disorders. The presentation highlighted the first clinical activity of a targeted protein degrader in the brain, indicating a significant breakthrough in therapeutic strategies for challenging diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.67%
Tags
none
-
News
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6
Rhea-AI Summary
Nurix Therapeutics, Inc. extends research program with Sanofi for STAT6 degrader, aiming to develop an oral drug targeting type 2 inflammation. Potential clinical candidate to be nominated within the next year. Collaboration highlights Nurix's expertise in protein modulation and Sanofi's capabilities in inflammation and immunology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.67%
Tags
none
News
Nurix Therapeutics to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Nurix Therapeutics, Inc. (NRIX) announced participation in upcoming healthcare conferences by key executives, including fireside chats and one-on-one meetings. The company aims to showcase its innovative approach in developing targeted protein modulation drugs for cancer and inflammatory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
conferences
-
News
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
Rhea-AI Summary
Nurix Therapeutics, Inc. extends research collaboration with Gilead Sciences, receiving a $15.0 million extension fee and potential future milestone payments totaling $1.7 billion. The collaboration aims to develop novel targeted protein degrader therapies for cancer and inflammatory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
none
-
News
Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)
Rhea-AI Summary
Nurix Therapeutics, Inc. (Nasdaq: NRIX) joins a diverse research team in the Cancer Grand Challenges competition to develop targeted protein degraders for pediatric cancer. The project aims to address five onco-fusion targets and improve cure rates for children with solid tumors, with a focus on previously undruggable fusion proteins. Nurix will leverage its DELigase technology and expertise in TPD optimization and development to contribute to the project.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
none
News
Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting
Rhea-AI Summary
Nurix Therapeutics, Inc. unveils NX-1607, the first inhibitor of CBL-B to enter clinical studies, showcasing innovation in targeted protein modulation. NX-1607 functions as an intramolecular glue, locking CBL-B in an inactive state to enhance T-cell activation. The drug is being tested in a Phase 1 trial as monotherapy and in combination with paclitaxel for various oncology indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.24%
Tags
none
Stock NRIX logo
Nurix Therapeutics Inc

Nasdaq:NRIX

NRIX Rankings

#2625 Ranked by Market Cap
#5036 Ranked by Stock Gains
N/A Ranked by Dividends

NRIX Stock Data

822.78M
37.68M
2.65%
97.95%
14.18%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
San Francisco

About NRIX

nurix is a science-focused company that is committed to bringing novel, first-in-class therapies to patients. nurix is a leader in discovering a new class of drugs that work by modulating e3 ubiquitin ligases within the ubiquitin proteasome system (ups). the ups is a regulatory network that controls protein stabilization and degradation – a function vital to the healthy life of a cell – offering therapeutic opportunities in multiple disease areas. nurix’s scientific team has established an innovative drug discovery platform to identify selective inhibitors or activators of the ups, enabling the development of novel therapeutics that can restore normal cellular homeostasis. nurix was founded by internationally recognized experts in the ups field and received its initial funding from leading life science investors, third rock ventures and the column group. in 2015, nurix entered into a multi-year strategic collaboration with celgene to discover and develop next-generation therapies targe